Development of a novel microneedle platform for biomarker assessment of atopic dermatitis patients

Abstract

AbstractBackgroundAtopic dermatitis (AD) is a chronic inflammatory skin disease whose pathogenesis, cause, and treatment have been extensively studied. The association of AD with Th2 cytokines is well known; therefore, the analysis of this association is crucial for the diagnosis and treatment of AD. This study aimed to present a new method for measuring protein biomarkers in patients with AD, before and after treatment, using minimally invasive microneedles.Materials and methodsFirst, hyaluronic acid‐loaded microneedle patches (HA‐MNs) for skin sample collection were fabricated. Next, after Institutional Review Board approval, 20 patients with AD were recruited and skin samples were taken before and after treatment using four different sampling techniques: (1) tape stripping, (2) hydrocolloid patches, (3) hollow microneedles, and (4) HA‐MNs. Lastly, proteins were isolated from the collected samples, and AD‐related biomarkers were analyzed by enzyme‐linked immunosorbent assay.ResultsProteins were successfully extracted from the skin samples collected by tape stripping, hydrocolloid patches, and HA‐MNs, except hollow microneedles. Interleukin (IL)‐4, IL‐13, and interferon‐γ were detected in the HA‐MNs only. By comparing the biomarker level correlation before and after treatment and the improvement score of the patients, we observed a significant negative correlation between IL‐4 and IL‐13 with an improvement in AD symptoms.ConclusionOverall, our results verified that HA‐MNs can be used to effectively analyze protein levels of biomarkers from skin metabolites of patients with AD and can be applied to monitor the treatment progress of patients with AD in a minimally invasive manner.